← All trials
NCT06525155
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2024
- Primary completion
- Sep 30, 2024
- Completion date
- Feb 28, 2025
- First posted
- Jul 29, 2024
- Last posted
- Aug 29, 2024
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rumah Sakit Pusat Angkatan Darat Gatot SoebrotoLead sponsor
- Rumah Sakit Pusat Angkatan Darat Gatot SoebrotoSponsor investigator
- Dexa Medica GroupCollaborator
- Rumah Sakit Pusat Angkatan Darat Gatot SoebrotoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.